A detailed history of Wells Fargo & Company transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Wells Fargo & Company holds 9,324 shares of ALXO stock, worth $52,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,324
Previous 8,296 12.39%
Holding current value
$52,587
Previous $123,000 16.26%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$10.95 - $16.79 $11,256 - $17,260
1,028 Added 12.39%
9,324 $103,000
Q4 2023

Feb 09, 2024

BUY
$4.81 - $15.38 $13,900 - $44,448
2,890 Added 53.46%
8,296 $123,000
Q3 2023

Nov 13, 2023

SELL
$4.19 - $7.35 $15,197 - $26,658
-3,627 Reduced 40.15%
5,406 $25,000
Q2 2023

Aug 15, 2023

BUY
$4.37 - $9.56 $17,165 - $37,551
3,928 Added 76.94%
9,033 $67,000
Q1 2023

May 12, 2023

BUY
$4.52 - $11.71 $14,974 - $38,795
3,313 Added 184.88%
5,105 $23,000
Q4 2022

Feb 13, 2023

BUY
$9.51 - $12.95 $8,996 - $12,250
946 Added 111.82%
1,792 $20,000
Q3 2022

Nov 14, 2022

SELL
$8.23 - $15.14 $22,369 - $41,150
-2,718 Reduced 76.26%
846 $9,000
Q2 2022

Aug 12, 2022

SELL
$5.89 - $19.46 $40,576 - $134,059
-6,889 Reduced 65.9%
3,564 $29,000
Q1 2022

May 16, 2022

SELL
$13.65 - $22.06 $55,678 - $89,982
-4,079 Reduced 28.07%
10,453 $177,000
Q4 2021

Feb 14, 2022

BUY
$21.49 - $74.4 $173,252 - $599,812
8,062 Added 124.61%
14,532 $312,000
Q3 2021

Nov 15, 2021

BUY
$52.51 - $80.91 $291,062 - $448,484
5,543 Added 597.95%
6,470 $478,000
Q2 2021

Aug 16, 2021

BUY
$52.2 - $75.23 $1,044 - $1,504
20 Added 2.21%
927 $50,000
Q1 2021

May 13, 2021

SELL
$62.84 - $87.68 $789,019 - $1.1 Million
-12,556 Reduced 93.26%
907 $67,000
Q4 2020

Feb 09, 2021

BUY
$34.11 - $112.26 $211,652 - $696,573
6,205 Added 85.49%
13,463 $1.16 Million
Q3 2020

Nov 05, 2020

BUY
$29.36 - $47.1 $213,094 - $341,851
7,258 New
7,258 $274,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $230M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.